Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 6, 2004, Pages 607-614

  Franchimont, N ^a   Putzeys, V ^a   Collette, J ^a   Vermeire, S ^b   Rutgeerts, P ^b   De Vos, M ^c   Van Gossum, A ^d   Franchimont, D ^d   Fiasse, R ^e   Pelckmansj, P ^f   Malaise, M ^a   Belaiche, J ^a   Louis, E ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d ERASME HOSPITAL   (Belgium)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f Gastroenterology   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; INFLIXIMAB; OSTEOCALCIN; PROCOLLAGEN C PROTEINASE;

ADOLESCENT; ADULT; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; CONTROLLED STUDY; CROHN DISEASE; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; OSTEOGENESIS;

EID: 4644250862     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02152.x     Document Type: Article

References (55)

1. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994; 107: 1031-9.
2. Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995; 10: 250-6.
3. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut 1997; 40: 313-9.
4. Gokhale R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BS. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 1998; 114: 902-11.
5. Robinson RJ, Al Azzawi F, Iqbal SJ, et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci 1998; 43: 2500-6.
6. Robinson RJ, Iqbal SJ, Al-Azzawi F, Abrams K, Mayberry JF. Sex hormone status and bone metabolism in men with Crohn's disease. Aliment Pharmacol Ther 1998; 12: 21-5.
7. Bjarnasson I, Macpherson A, Mackenzie C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1996; 40: 228-33.
8. Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998; 93: 1483-90.
9. Vestergaard P, Mosekilde F. Fracture risk in patients with coeliac disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16416 patients in Denmark. Am J Epidemiol 2002; 156: 1-10.
10. Vestergaard P, Krogh K, Renjmark L, Lauberg S, Mosekilde L. Fracture risk is increased in Crohn's, but not in ulcerative colitis. Gut 2000; 46: 176-81.
11. Bernstein C, Blanchard J, Leslie W, Wajda A, Yu B. The incidence of fracture among patients with inflammatory bowel disease. Ann Int Med 2000; 133: 795-9.
12. Van Staa T, Brusse L, Javaid M, Leufkens H, Cooper C, Arden NK. Inflammatory bowel disease and the risk of fracture. Rheumatology 2003; 42(Suppl. 1): 128.
13. Bischoff SC, Herrmann A, Goke M, Manns MP, von zur Muhlen A, Brabant G. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 1997; 92: 1157-63.
14. Silvennoinen JA. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med 1996; 239: 131-7.
15. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37: 71-6.
16. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983; 309: 265-8.
17. Compston JE. Detection of osteoporosis in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 1997; 9: 931-3.
18. Szulc P, Meunier PJ. Is vitamin-K deficiency a risk factor for osteoporosis in Crohn's disease? Lancet 2001; 357: 1995-6.
19. Hyams JS, Wyzga N, Kreutzer DL, Justinich CJ, Gronowicz GA. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. J Pediatr Gastroenterol Nutr 1997; 24: 289-95.
20. Sylvester FA, Wyzga N, Hyams JS, Gronowicz GA. Effect of Crohn's disease on bone metabolism in vitro: a role for interleukin-6. J Bone Miner Res 2002; 17: 695-702.
21. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002; 97: 2962-72.
22. Targan S, Hanauer S, van Deventer SJH, et al. A short-term study of chimeric antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997; 337: 1029-35.
23. Present DH, Rutgeerts P, Targan S, et al. Inflixirnab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
24. Rutgeerts P, D'Haens G, Targan S, et. al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-9.
25. Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
26. D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116: 1029-34.
27. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000; 95: 3469-77.
28. Gilbert L, He X, Farmer P, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000; 141: 3956-64.
29. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000; 275: 4858-64.
30. Tsuboi M, Kawakami A, Nakashima T, et al. Tumor necrosis factor-alpha and interleukin-1 beta increase the Fas-mediated apoptosis of human osteoblasts. J Lab Clin Med 1999; 134: 222-31.
31. von Tirpitz C, Reinshagen M. Management of osteoporosis in patients with gastrointestinal disease. Eur J Gastroenterol Hepatol 2003; 15: 869-76.
32. Delmas DP. How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone 2000; 27: 1-3.
33. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with anti-resorptive drugs. Am J Med 2000; 112: 281-9.
34. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002; 17: 1-10.
35. Li Z, Meredith MP, Hoseyni MS. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 2001; 20: 3175-88.
36. Stockbrügger RW, Schoon EJ, Bollani S, et al. Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease. Aliment Pharmacol Ther 2002; 16: 1519-27.
37. Johnell O, Oders A, De Laet C, Garnero P, Delmas PD, Kanis JA. Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int 2002; 13: 523-6.
38. Bjarnasson NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001; 12: 922-30.
39. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18: 1051-6.
40. Bauer DC, Black DM, Garnero P, et al. Reduction in bone turnover predicts hip, non-spine, and vertebral fracture in alendronate treated women: the fracture intervention trial. Osteoporos Int 2002; 13(Suppl. 1): S521.
41. Louis E, El Ghoul Z, Vermeire S, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 2004; 19: 511-9.
42. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000; 119: 639-46.
43. Reginster JY, Sarkar S, Zegels B, et al. Reduction in P1NP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 2004; 34: 344-51.
44. Schulte C, Dignass AU, Mann K, Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis 1998; 4: 268-75.
45. Schoon EJ, Geerling BG, Van Dooren IM, et al. Abnormal bone turnover in long-standing Crohn's disease in remission. Aliment Pharmacol Ther 2001; 15: 783-92.
46. D'Haens G, Verstraete A, Cheyns K, Aerden I, Bouillon R, Rutgeerts P. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease. Aliment Pharmacol Ther 1998; 12: 419-24.
47. Von Tirpitz C, Epp S, Klaus J, et al. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. Eur J Gastroenterol Hepatol 2003; 15: 1165-70.
48. von Tripitz C, Klaus J, Steinkamp M, et al. Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 2003; 17: 807-17.
49. Abitbol V, Mary JY, Roux C, et al. Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment Pharmacol Ther 2002; 16: 919-27.
50. von Tirpitz C, Klaus J, Brückel J, et al. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2000; 11: 19-24.
51. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349: 1207-15.
52. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-68.
53. Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000; 191: 275-86.
54. Gilbert L, He X, Farmer P, et al. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem 2002; 277: 2695-701.
55. Boureille A, Doubremelle M, Maugars Y, Galmiche J. Reversibility of decreased bone mineral density after infliximab-induced remission in Crohn's disease. Gut 2002; 51(Suppl. III): A237.